Geriatric Nutritional Risk Index Predicts Adverse Outcomes in Human Malignancy: A Meta-Analysis

Table 2

Stratification analysis for the meta-analysis with overall survival (OS) in patients with malignancies.

Subgroup	No. of studies	No. of patients without risk	No. of patients at risk	Pooled HR (95% CI)	Heterogeneity
					(%)	value
Altogether	13	2,030	993	2.01 (1.49-2.71)	85.0	≤0.001
Publishing time
≥2018	10	1,565	811	1.86 (1.38-2.51)	84.4	≤0.001
<2018	3	465	182	2.21 (1.31-3.75)	69.3	0.021
Country
Japan	8	1,181	561	2.40 (1.86-3.10)	44.7	0.081
China	5	849	432	1.43 (1.08-1.90)	72.2	0.031
Sample capacity
≥240	7	1,355	742	1.45 (1.13-1.85)	70.5	0.002
<240	6	675	251	2.66 (2.00-3.55)	42.6	0.107
Dividing line for GNRI
≥98	8	1,051	452	2.07 (1.41-3.03)	86.9	≤0.001
<98	5	979	541	1.84 (1.49-2.28)	6.3	0.371
Cancer system
Hematological	5	646	539	2.02 (1.27-3.20)	69.4	0.011
Digestive	6	992	366	1.74 (1.25-2.43)	84.0	≤0.001
Urinary	1	273	66	1.80 (1.13-2.87)	—	—
Respiratory	1	119	22	4.58 (2.36-8.88)	—	—
Primary therapy
Resection	6	927	333	1.90 (1.25-2.88)	88.6	≤0.001
Chemotherapy	4	615	507	1.97 (1.12-3.49)	76.3	0.005
Radiotherapy	1	184	55	2.09 (1.32-3.30)	—	—
Others	2	304	98	1.95 (1.33-2.86)	0.0	0.552
HR source
Crude	9	1,587	841	1.78 (1.54-2.06)	0.00	0.441
Data	4	443	152	2.71 (1.06-6.90)	92.9	≤0.001
Analytic method
Univariate	5	596	215	2.62 (1.28-5.35)	92.7	≤0.001
Multivariate	8	1,434	778	1.70 (1.46-1.99)	0.0	0.590